Antibody Targeting of Cell-Bound MUC1 SEA Domain Kills Tumor Cells
Open Access
- 1 July 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (13) , 3324-3336
Abstract
The cell-surface glycoprotein MUC1 is a particularly appealing target for antibody targeting, being selectively overexpressed in many types of cancers and a high proportion of cancer stem–like cells. However the occurrence of MUC1 cleavage, which leads to the release of the extracellular α subunit into the circulation where it can sequester many anti-MUC1 antibodies, renders the target problematic to some degree. To address this issue, we generated a set of unique MUC1 monoclonal antibodies that target a region termed the SEA domain that remains tethered to the cell surface after MUC1 cleavage. In breast cancer cell populations, these antibodies bound the cancer cells with high picomolar affinity. Starting with a partially humanized antibody, DMB5F3, we created a recombinant chimeric antibody that bound a panel of MUC1+ cancer cells with higher affinities relative to cetuximab (anti-EGFR1) or tratuzumab (anti-erbB2) control antibodies. DMB5F3 internalization from the cell surface occurred in an efficient temperature-dependent manner. Linkage to toxin rendered these DMB5F3 antibodies to be cytotoxic against MUC1+ cancer cells at low picomolar concentrations. Our findings show that high-affinity antibodies to cell-bound MUC1 SEA domain exert specific cytotoxicity against cancer cells, and they point to the SEA domain as a potential immunogen to generate MUC1 vaccines. Cancer Res; 72(13); 3324–36. ©2012 AACR.Keywords
This publication has 46 references indexed in Scilit:
- Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significanceBreast Cancer Research, 2011
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab PasudotoxClinical Cancer Research, 2011
- Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist AntibodyClinical Cancer Research, 2011
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- MUC1 oncoprotein is a druggable target in human prostate cancer cellsMolecular Cancer Therapeutics, 2009
- Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancerBreast Cancer Research, 2009
- Mammosphere‐derived gene set predicts outcome in patients with ER‐positive breast cancerThe Journal of Pathology, 2009
- Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1Blood, 2008
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucinNature Structural & Molecular Biology, 2005